Aquavit Pharmaceuticals

About Us


Sobin Chang, MPH, Chief Executive Officer

Over 20 years of experience in Management, Marketing, and Research in pharmaceuticals, devices, biologics as well as nutraceuticals from recognized brand BOTOX® to $7.5B oncology portfolio. She built her corporate track record with Pfizer, Bayer, Schering-Plough(Merck), Novartis and Allergan. Her breadth of experience in various therapeutic areas includes neuroscience, dermatology, infectious disease, allergy & immunology and oncology, which lead to over 20 inventions. She is a trained pharmacoeconomist and has over 60 publications. She was recently the opening keynote speaker for Big data in Pharma conference in Philadelphia. She served at the US Department of Health and Human Services, the Division of Drug Marketing, Advertising and Communications of the Food and Drug Administration (FDA DDMAC) providing guidance on the FDA Modernization Act. She received her B.A. Honors in Mathematics with Magna Cum Laude from University of Missouri-Columbia and M.P.H and post-doctoral fellowship in Biostatistics, Regulatory Affairs and Pharmacoeconomics from Yale School of Medicine. She is currently serving as a Director of the Board at AYAPH (Association of Yale Alumni in Public Health) and Chair, Business and Industry Committee.

George Simeon, MPH. MBA. PhD. SVP Corporate Development

Prior to joining Aquavit, George lead the Healthcare Practice of Sollers Partner and has over 25 years of experience in the healthcare sector working with multinational corporations. He has significant experience in pharmaceuticals, medical devices, IVD, and healthcare convergence technologies. He has been involved in a number of cross-border transactions and advised large firms and start-ups on global business strategy and fundraising. Prior to Sollers, he worked with SK Telecom’s Healthcare Division in M&A and global strategic alliances. He worked across Europe and the USA as an executive with Johnson & Johnson as Vice-President for Cordis Neurovascular Europe and with GHX Europe as a commercial Vice-President. He also spent several years with Novartis Global Headquarters in Switzerland working on projects in their CNS portfolio in Health Economics and Pricing. He has also founded two start-ups and advised GS1 on their global entry and expansion into the Healthcare sector. George is a graduate of INSEAD (MBA), Yale University School of Medicine (MPH), Bocconi (PhD ABD) and the University of Ottawa (Economics).

David J. Goldberg, MD, JD, Chief Medical Officer

David is a Clinical Professor of Dermatology and Director of Laser Research at NY’s Mount Sinai School of Medicine. He is also Clinical Professor of Dermatology and Chief of Dermatologic Surgery at Rutger’s New Jersey Medical School. He is current Chief of Dermatology at NJ’s Hackensack University Medical Center. He has published over 150 peer-reviewed manuscripts and is author of books on Laser Hair Removal; Cellulite and Fat Removal, Acne and Rosacea, Ablative and Non-ablative Skin Rejuvenation; Photodamaged Skin, Complications in Cutaneous Laser Surgery, Laser Dermatology, and Dermal Fillers. He is Editor in Chief of the Journal of Cosmetic and Laser therapy and serves as an editorial board member of both Lasers in Surgery and Medicine and Dermatologic Surgery.

David is also an attorney and he currently serves as an Adjunct Professor of Law and teaches a course entitled “Advances in Health Care Law”. Dr. Goldberg has served as President of ASLMS and is or was on the Board of Directors of AAD, ASLMS and ASDS. He received his law degree from Fordham University School of Law and earned his medical degree from Yale University School of Medicine. He completed his dermatology residency and dermatologic surgical fellowship at New York University Medical Center.

David Shafer, MD, FACS, Chief Medical Technology Officer

David’s passion for innovation, technology, & improving the overall patient experience, has led him to create the world’s first-ever plastic surgery themed iPhone application. The App features over 1000 interactive FAQs about plastic surgery. Dr. Shafer launched the world’s first Vectra XT 3D Imaging System, allowing patients to view 3D simulated procedures on their own body prior to their surgery. Dr. Shafer has repeatedly been voted TOP DOC for Botox, Liposuction, Tummy Tuck, and Facelift among many other categories. Dr. Shafer is a NYC double board certified plastic surgeon, a Diplomat of the American Board of Plastic Surgery & a Member of the American Society of Plastic Surgeons. He was trained at the world renowned Mayo Clinic, which is consistently ranked as the best in class for hospitals and surgical training. Additionally, he completed a prestigious fellowship at MEETH, making him an expert in Aesthetic Surgery

Kwonsoo Chun, PhD, Chief Engineer

Kwonsoo is a highly talented and accomplished engineer with specialization in identifying clinical needs, designing desired medical devices, and providing engineering solutions. He has extensive R&D experience and patents from Baylor College of Medicine’s Department of Neurosurgery. He has a broad background in biomedical engineering, electrical engineering, and mechanical engineering. He has experiences in designing and developing medical devices in order to treat spinal instability, cardiovascular disease, and obesity. At Stanford University, he researched on robotics and haptics and conducted actuator control such as motor and solenoid with operating a micro-processor. His previous works resulted in startups and publications through a number of collaborations with medical doctors and engineering team. He currently holds a faculty position at Baylor College of Medicine and has numerous publications in peer-reviewed journals. He received his Ph.D. in Mechanical Engineering from Stanford University.

Back to Top

Advisory Board

Brian O’Callaghan

Brian O’Callaghan is currently the President & Chief Executive Officer of Petra Pharma, a New York based biotech company. He was previously President and Chief Executive Officer at Acucela, Sonrgy, and Sangart respectively. He has over 25 years of leadership experience in the biotechnology and pharmaceutical industries, having lived and worked in 5 different countries and both sides of the US, working for such companies as Pfizer in the UK, Merck Serono in Germany, BioPartners in Switzerland, Bayer in Ireland, and Novartis in the US. He has run both public and private companies, gaining extensive experience within areas such as fundraising, IPO's, BD, M&A, as well as all areas of product development and commercialization. He also brings extensive Board experience having served on numerous corporate, industry and non profit boards.

Jon Lippin

Mr. Lippin is President & CEO of Bolder Industrial Performance Services. Prior to Bolder, he was Honeywell’s Vice President General Manager of Asia Pacific in Shanghai, China, Vice President and General Manager Lifecycle Solutions and Services in Bracknell, UK and Vice President of Global Sales in US.

Michael Piraino, CPA

Michael Piraino serves as the Chief Financial Officer and Executive Vice President of Accelrys Software Inc. With almost 30 years experience in Senior Executive and Financial roles, Mr. Piraino has broad depth of expertise in financial and operational management. He has served in the past in Accelrys Software, CRS Retail Technology Group, CEO Resources, Symyx Technologies, Epicor Software Corporation, Accelrys, Enfrastructure (now known as TechSpace), SM&A, Data Processing Resources Corporation. He has served as senior management in bitotech companies such as Imagyn Medical Technologies, Syncor International Corporation, Total Pharmaceutical Care. Mr. Piraino is a Certified Public Accountant, and member of the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants. He holds a B.S. Degree in Accounting from Loyola University.

B.G. Rhee, Ph.D

B.G. Rhee is the Vice Chairman of CKD Pharma. He was previously the CEO of Green Cross Holdings, Inc. and the President of Green Cross Corp., President and CEO of Expression Genetics, Head of Pharmaceutical Business Unit of Samyang Corporation and Head of Drug Development Center of LG Chem (Currently LG Life Science). B.G. Rheewas was also President of BIO Korea, Member of the National Academy of Engineering Korea, Co-Chairman of HT Forum, and Member of the Science and Technology Committee, Federation of Korean Industries. He got his education from Rice University and Seoul National University.

Youngjay Paik, PhD

Young-Jay is currently the Senior Director of Google, EVP Google Korea. He wa previously the CEO of Blizzard Entertainment in Korea. He has experiences in working at global consulting firms including McKinsey & Company and Booz & Co., where he carried out diverse projects such as marketing strategy, operational improvement, new business development, change management, performance management, etc. in banking, telecom, healthcare, real estate, automotive, high tech, and heavy industries. Young-Jay earned a BA in Anthropology from Seoul National University, a Ph.D in Anthropology from Yale University, and a MRED from USC.

Sharon Tonetta, PhD

Sharon Tonetta is Vice President of Regulatory Affairs of Valeant Pharmaceuticals. She was previously Vice President of Global Regulatory Affairs at Bausch & Lomb, Allergan, Maxim Pharmaceuticals, Baxter Healthcare, and Baxter International. Sharon Tonetta has a Ph.D. in Animal Science & Physiology from Michigan State University and a B.A. in Biology from Cornell College.

Sandeep Duttagupta, PhD

Sandeep Duttagupta, PhD, Principal and Vice President at CBPartners, has spent almost two decades in the areas of value assessment, market access, pricing and health economics of pharmaceutical and biotechnology products. In his current role, Dr. Duttagupta is responsible to build the health care practice in Emerging Markets for CBPartners. Prior to joining the consulting firm, Dr. Duttagupta was the Head of Market Access & Pricing supporting Pfizer's Emerging Market Business Unit. A trained health economist, Sandeep was previously responsible for providing Health Outcomes support to the countries in Asia, Latin America, Africa, and Middle East. Sandeep joined Pfizer in 1996, and was responsible for planning and implementing health economic and outcomes research strategies. Sandeep has a B.S. in Pharmacy from Calcutta, India and Ph.D. in Health Care Administration from University of Louisiana, Monroe.

Thomas A. Albright

Tom has 35 years of experience in the field of pharmaceutical, biologic, device and aesthetic-related sales, marketing and general management roles. He currently serves as the CEO of Recros Medica and Chairman and CEO of Andrew Technologies. Prior to that, he was president of the topical aesthetic division at Syneron Medical, Head of North American marketing at Nobel Biocare. His medical aesthetic experience commenced with Allergan (2000 – 2008), where he led the launch of BOTOX® Cosmetic and the commercial development of Latisse®. He was also the alliance manager for the collaboration between Allergan and GlaxoSmithKline in China, Japan, and the US. In 1983, he commenced his career in healthcare with the Parke-Davis division of Warner Lambert, where he held sales and marketing leadership roles, including the 1997 launch of Lipitor®, among other brands. Tom has a BS in biology from The Citadel and an MBA in marketing from Mercer University.

Back to Top